Cancer-Related Cognitive Impairment in Breast Cancer: Current State of Knowledge, Mechanisms, Diagnosis, Prevention and Treatment
Authors:
- Federica AndreisFAFederica Andreis
- Chiara DeoriCDChiara Deori
- Valentina GiubileoVGValentina Giubileo
- Chiara AbeniCAChiara Abeni
- Irene CaramellaICIrene Caramella
- Sara CherriSCSara Cherri
- Brunella Di BiasiBBBrunella Di Biasi
- Michela LibertiniMLMichela Libertini
- Silvia NoventaSNSilvia Noventa
- Chiara OgliosiCOChiara Ogliosi
- Ester OnedaEOEster Oneda
- Tiziana ProchiloTPTiziana Prochilo
Open Access
Abstract
Cancer-related cognitive impairment (CRCI), also known as chemobrain or chemofog, is characterized by subjective and/or objective changes in attention, executive functions, memory, and processing speed in patients with non-CNS cancers, particularly women with breast cancer. This structured narrative review synthesizes current evidence on mechanisms, neuropsychological assessment, neuroimaging correlates, clinical and demographic risk factors, emerging artificial intelligence and machine learning applications, and non-pharmacological approaches to CRCI in breast cancer. A structured literature search was conducted using PubMed/MEDLINE, PsycInfo, and Clinical Key up to May 2026, with emphasis on studies published between 2023 and 2026. Peer-reviewed English-language studies involving adult breast cancer populations and addressing predefined thematic domains of CRCI were considered. Given the heterogeneity of study designs, assessment tools, interventions, and outcomes, the findings were synthesized narratively. Current evidence supports a multifactorial model of CRCI involving neurobiological, treatment-related, psychological, and behavioral mechanisms. Neuroinflammation, endocrine disruption, oxidative stress, glial alterations, and structural or functional brain changes may contribute to cognitive symptoms; however, the strength of evidence varies, and many findings remain correlational or preclinical. Non-pharmacological interventions, including cognitive training, physical activity, mindfulness-based and psychological approaches, and multimodal digital programs, appear promising as supportive strategies. However, evidence remains heterogeneous, with benefits more consistently reported for patient-reported outcomes, fatigue, emotional distress, and quality of life than for objective neuropsychological performance. CRCI in breast cancer should be approached as a heterogeneous condition requiring early recognition, standardized assessment, and multidisciplinary supportive care. Future research should prioritize longitudinal designs, harmonized endpoints, and a clearer distinction between subjective and objective outcomes.Keywords
This publication has 65 references indexed in Scilit:
- Artificial intelligence across the cancer care continuumCancer, 2025
- Effect of Cognitive Training on Cancer‐Related Cognitive Impairment in Patients With Breast Cancer: A Systematic Review and Meta‐AnalysisPsycho-Oncology, 2025
- Donepezil for cancer-related cognitive impairment: systematic review and meta-analysisClinical and Experimental Medicine, 2025
- Advances in risk prediction models for cancer-related cognitive impairmentClinical and Experimental Medicine, 2025
- Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE): A randomized controlled trialCancer, 2024
- Neurotoxicity of the antineoplastic drugs: “Doxorubicin” as an exampleJournal of Molecular Histology, 2024
- Voice-Activated Cognitive Behavioral Therapy for InsomniaJAMA Network Open, 2024
- A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effectsCancer Medicine, 2023
- The impact of mindfulness on cancer‐related cognitive impairment in breast cancer survivors with cognitive complaintsCancer, 2023
- Interventions promoting cognitive function in patients experiencing cancer related cognitive impairment: A systematic reviewPsycho-Oncology, 2022